From liters to solutions

Introduction

For years, the narrative of the CDMO (Contract Development and Manufacturing Organization) industry has been a story of “giants”. Their appeal is obvious: massive scale, global footprints, and multi-billion dollar facilities capable of scaling-up blockbusters.

However, the “bigger is better” era is facing a structural reckoning. While the giants will always have their place in large-scale biologics, the structural evolution of drug development is quietly favoring a different kind of winner in the pharmaceutical landscape: the mid-sized European biotech CDMO.

As the industry moves away from “one-size-fits-all” toward high-complexity, low-volume personalized therapies, the strategic value of agility is beginning to outweigh the raw power of scale. Pharmaceutical companies increasingly seek specialized CDMO partners capable of combining biologics manufacturing expertise, technical precision, and strategic flexibility.  Here is why the tide is turning.

The fragmentation of biologic pipelines

Drug development is increasingly focused on smaller, more targeted indications, such as orphan diseases and precision oncology. These programs do not require the massive, multi-thousand-liter bioreactors found in mega-plants.

Instead, they demand specialized biological partners capable of handling modest commercial volumes with extreme technical precision. In this landscape, flexibility is more resilient than raw scale.

For modern biologics outsourcing, the ability to adapt to niche therapeutic programs has become a decisive strategic advantage.

Biological complexity requires specialized CDMO expertise

The technical bar is rising across the entire spectrum of biological modalities. Even in hybrid molecules, the biological component is often the most critical hurdle:

• Biological APIs: In the production of High Potency APIs (HPAPIs), success depends on the synthesis of complex biological active ingredients that maintain functional integrity.
• Antibody Engineering for ADCs: For sophisticated Antibody-Drug Conjugates (ADCs), the focus is on the precision-engineered antibody vehicle. This component must be developed for high specificity and stability to ensure the entire conjugate functions correctly.
• Intricate Expression Systems: Mid-sized partners excel at solving folding and stability issues in recombinant proteins and enzymes—puzzles that standardized “mega-factories” are often not equipped to address.

A specialized biotech CDMO is not defined by manufacturing scale alone, but by its ability to solve complex biological development and production challenges.

For a mid-sized biotech partner, success isn’t measured by how many liters can be fermented, but by how many complex problems can be solved. Those high-stakes, intricate programs where personal scientific oversight and tailor-made processes are the only way to ensure success.

Supply chain diversification is driving demand for european CDMOs

The “efficiency at all costs” model of the last decade has been replaced by a “resilience at all costs” mindset.

Recent global disruptions have taught the industry that relying on a single, massive manufacturing partner creates significant concentration risk. Many companies now prefer a portfolio approach, combining a large CDMO with specialized biological partners.

Furthermore, geopolitical shifts and increasing regulatory scrutiny are driving pharmaceutical companies toward European partners.

By choosing ‘geographic resilience’ over distant, high-risk supply chains, companies working in pharmaceutical outsourcing and biologics manufacturing gain access to stable regulatory environments, high production standards, and greater long-term continuity.

Why mid-sized CDMOs offer greater strategic agility

Mega-platforms require continuous, multi-billion-dollar investments to maintain their footprint. In contrast, mid-sized organizations expand incrementally by adding specific biological capabilities: HPAPI suites, specialized antibody labs, or niche fermentation technologies. This agility allows them to pivot quickly to meet the unique needs of an innovator, providing a “speed-to-market” advantage that scale alone cannot match.

In the modern outsourcing landscape, the ability to solve a complex biological problem has become more attractive than simply providing the largest tank. While the giants will continue to handle bulk manufacturing, the high-stakes world of specialized biologics belongs to the agile, mid-sized experts.

The bottom line

In the modern outsourcing landscape, scale offers power, but specialization builds resilience. As the industry transitions from the era of blockbusters to the age of precision biologics, the “one-size-fits-all” model is giving way to a more partner-driven approach.

At Diatheva, we believe that the true value of a partnership lies in scientific specialization and strategic flexibility. Our focus is not on the raw volume of liters fermented, but on the complexity of the biological problems we solve. By combining rigorous production with the agility to pivot toward niche technologies, from recombinant enzymes to specialized antibody vehicles — we ensure that innovation is never sidelined by the constraints of a “mega-factory”.

The future of pharma isn’t just about how much you can make; it is about the technical integrity and strategic flexibility with which you make it. In a world of increasing volatility, the most valuable asset isn’t the largest tank—it’s the most capable expert.